PriceTargets.com logo

Telomir Pharmaceuticals - TELO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 1,002.94%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 1 Strong Buy Ratings
$1.36 As of 12/4/2025 05:00 PM ET
▲ +0.04 (3.03%)

This chart shows the closing price for TELO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Telomir Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TELO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TELO

Analyst Price Target is $15.00
▲ +1,002.94% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Telomir Pharmaceuticals in the last 3 months. The average price target is $15.00, with a high forecast of $15.00 and a low forecast of $15.00. The average price target represents a 1,002.94% upside from the last price of $1.36.

This chart shows the closing price for TELO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 investment analysts is to moderate buy stock in Telomir Pharmaceuticals. This rating has held steady since September 2025, when it changed from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
2/21/2025Rodman & RenshawInitiated CoverageBuy$15.00
2/20/2025RODMAN&RENSHAWUpgradeStrong-Buy
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
8/6/2025
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 9 positive mentions
  • 5 negative mentions
  • 4 very negative mentions
Mentions as of
11/4/2025
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Telomir Pharmaceuticals logo
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
Read More

Today's Range

Now: $1.36
Low: $1.30
High: $1.38

50 Day Range

MA: $1.45
Low: $1.27
High: $1.93

52 Week Range

Now: $1.36
Low: $1.12
High: $7.08

Volume

201,004 shs

Average Volume

643,241 shs

Market Capitalization

$46.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Telomir Pharmaceuticals?

The following equities research analysts have issued research reports on Telomir Pharmaceuticals in the last twelve months: Rodman & Renshaw, RODMAN&RENSHAW, and Weiss Ratings.
View the latest analyst ratings for TELO.

What is the current price target for Telomir Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Telomir Pharmaceuticals in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 1,002.9%. Rodman & Renshaw has the highest price target set, predicting TELO will reach $15.00 in the next twelve months. Rodman & Renshaw has the lowest price target set, forecasting a price of $15.00 for Telomir Pharmaceuticals in the next year.
View the latest price targets for TELO.

What is the current consensus analyst rating for Telomir Pharmaceuticals?

Telomir Pharmaceuticals currently has 1 sell rating, 1 buy rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TELO.

What other companies compete with Telomir Pharmaceuticals?

Other companies that are similar to Telomir Pharmaceuticals include Quince Therapeutics, Innate Pharma, Cartesian Therapeutics, FitLife Brands and Actuate Therapeutics. Learn More about companies similar to Telomir Pharmaceuticals.

How do I contact Telomir Pharmaceuticals' investor relations team?

Telomir Pharmaceuticals' physical mailing address is 855 N Wolfe Street, Suite 601, Baltimore, MD 21205, United States. The company's listed phone number is (737)-289-0835 and its investor relations email address is [email protected]. The official website for Telomir Pharmaceuticals is telomirpharma.com. Learn More about contacing Telomir Pharmaceuticals investor relations.